Search PubMed⌕ Search

Biomedical subjects

M Gallet

Publications and source records attributed to M Gallet.

At least 37 records · Page 2Linked to original sources
PubMed1986

[Current concepts in cellular ischemia: role of trimetazidine].

Comparative clinical trials have already enabled to appreciate the clinical efficacy of trimetazidine (TMZ) during chronic coronary angina. Two recent controlled studies have been done in patients with chronic stable angina, and conducted in double blind versus placebo, with randomized assignment of the treatments. They showed that TMZ administered either in a single dose (60 mg), or for one month at a daily dose of 60 mg, enabled on the one hand an improvement of the stress ability: increase of the total work (respectively 31 and 38 per cent), and of the duration of the stress (17 per cent in an average), and on the other hand, the recession of the myocardial ischemic threshold: increase in the time of appearance of a 1 mm sub-shift of ST (respectively 7 and 17 per cent). The absence of alteration, in each of the placebo and trimetazidine groups, of the cardiac frequency and systolic arterial blood pressure at rest and the double product on exertion, suggested a different mechanism of action from the usual anti-angina medications. Many experimental works have been able to show that trimetazidine has an intra-cellular "anti-ischemic" activity and a cardioprotective effect which would be present during ischemic phases. The anti-ischemic activity would counteract the harmful effects of hypoxia by maintaining cellular energetic reserves, and by decreasing the deadly membrane effects of the free radicals, particularly passive permeability to potassium. In the same experimental conditions of ischemia, the cardioprotective effect is demonstrated by the decrease of the creatine kinase leakage and the upholding or the rapid recovery of the myocardial electric activity.(ABSTRACT TRUNCATED AT 250 WORDS)

Angina Pectoris↗
PubMed1986

Antihypertensive effects of tertatolol: 3-month comparative study against acebutolol.

Thirty-two hypertensive patients (mean age 52.9 +/- 1.7 years) with a supine diastolic blood pressure (DBP) between 95 and 130 mm Hg (mean 104.3 +/- 0.8) received, following a randomized allocation, either tertatolol 5 mg (n = 16) or acebutolol 400 mg (n = 16) in a single daily dose. The 2 drugs were administered during a 3-month treatment period (from day 0 to day 90) in a single-blind fashion. At rest (n = 32), the decrease of supine systolic blood pressure (SBP) reached 27.3 mm Hg after 1 month of tertatolol treatment (from day 0 to day 30; p less than 0.01); there was a further decrease of 5.1 mm Hg from day 30 (D30) to day 90 (D90) (NS). The corresponding decreases after acebutolol treatment reached respectively 22.3 mm Hg (p less than 0.01) and 5.7 mm Hg (p less than 0.05). Similar results were observed in the upright position. The decrease of supine DBP reached 14.0 mm Hg in patients treated with tertatolol from D0 to D30 (p less than 0.01); a further decrease of 2.9 mm Hg occurred from D30 to D90 (NS). The corresponding decreases in patients administered acebutolol reached respectively 7.6 mm Hg (p less than 0.01) and 5.2 mm Hg (p less than 0.01). Similar results were observed in the upright position. On submaximal exercise (ergometric bicycle; n = 18), the decrease of SBP reached respectively 31.3 mm Hg during tertatolol treatment from D0 to D30 (p less than 0.01) and 8.8 mm Hg from D30 to D90 (NS).(ABSTRACT TRUNCATED AT 250 WORDS)

Acebutolol↗
PubMed1986

[Diltiazem and digoxin interaction. Development of digoxin plasma levels and electrocardiographic parameters in healthy subjects].

In order to determine the interaction between diltiazem and digoxin, plasma digoxin concentrations and the principal ECG parameters (24 hour Holter monitoring) were measured in 10 healthy volunteers under basal conditions (P0), with 0.375 mg/day of digoxin (P1 = 17 days), during association with 240 mg/day of diltiazem (P2 = 17 days) and then again on digoxin alone (P3 = 10 days). The addition of diltiazem was associated with a 20.4% rise in plasma digoxin concentrations (0.59 ng/ml vs 0.49 ng.ml). There was no significant variation of plasma digoxin after withdrawal of diltiazem; in some cases it remained unchanged, in others it fell or continued to rise. During the administration of digoxin and diltiazem, the mean RR period and the duration of the maximal pauses increased (p less than 0.05); the RR interval also increased (p less than 0.01) but the mean QRS duration and the QTc interval did not change significantly with respect to their values on digoxin alone. After withdrawal of diltiazem, the PR interval was the only parameter to decrease significantly (p less than 0.05). These results suggest that patients receiving this drug association should be followed up carefully.

Adult↗
PubMed1979

[Prevention and treatment of urinary infection in patients with an indwelling catheter: continuous vesical irrigation with a mixed antibiotic solution of neomycin and polymyxin B].

A method of continuous lavage of the bladder using a solution containing a mixture of Neomycine and Polymyxine-B was tried out in 32 patients with indwelling urinary catheters. To do this, a three-channel catheter was used, lubricated with an antibacterial cream and connected to a plastic container which could be emptied without removing the catheter. This method of treatment, which was effective, well tolerated and simple to use, would appear to be a useful addition to the prevention and treatment of urinary infections in patients with in-dwelling catheters.

Adolescent↗
PubMed1976

[Potent natural inhibitors of tobacco mosaic virus multiplication].

The hypersensitivity reaction in Nicotiana tabacum var. Xanthi n.c. infected with Tobacco mosaic virus (T.M.V.) leads to the production of aromatic amides (ferulylputrescine, diferulylputrescine, p-coumarylputrescine and di-p-coumarylputrescine) inthe cells around the necroses. Similar compounds are formed in Xanthi plants after floral induction. p-coumarylputrescine, di-p-coumarylputrescine and caffeylputrescine strongly inhibit T.M.V. multiplication.

Antiviral Agents↗